Skip to Content Facebook Feature Image

HKBU scientist's Automated Multiplex Diagnostics System recommended by WHO as an innovative health technology for low-resource contexts

Business

HKBU scientist's Automated Multiplex Diagnostics System recommended by WHO as an innovative health technology for low-resource contexts
Business

Business

HKBU scientist's Automated Multiplex Diagnostics System recommended by WHO as an innovative health technology for low-resource contexts

2024-12-03 15:03 Last Updated At:15:25

HONG KONG, Dec. 3, 2024 /PRNewswire/ -- The Automated Multiplex Diagnostics System developed by Professor Terence Lau, Interim Chief Innovation Officer of Hong Kong Baptist University (HKBU), has been recommended in the 2024 Compendium of Innovative Health Technologies for Low-resource Settings published by the World Health Organization (WHO) as an innovative technology with the potential to contribute positively to health systems in low- and middle-income countries.

Enabling rapid detection of multiple pathogens

The Compendium published by WHO identifies commercially available solutions and prototypes which help address the challenge of low-resource settings, particularly in low- and middle-income countries, in their access to appropriate, affordable, effective, and safe health technologies to tackle infectious diseases, as well as the increasing burden of non-communicable diseases brought about by cardiovascular issues, cancers, chronic respiratory conditions, and diabetes.

The System can fully automate conventional laboratory-based PCR (polymerase chain reaction) processes in an all-in-one system with three elements: an analytical machine, a microfluidic reagent cartridge, and software. Its proprietary design enables the simultaneous detection of 42 respiratory pathogens, including 28 viruses, 11 bacteria and 3 fungi, in less than 1.5 hours without the need for a resource-intensive laboratory, multiple equipment, or specially trained technicians while maintaining superior sensitivity and specificity.

Technology ready for market access

Apart from its extraordinary performance, it also provides advantages in terms of costs, turnaround time, and the ability to analyse more targets at once. It is selected as one of the 21 highlighted health technologies in the Compendium in the category of prototypes. Its technology readiness level (TRL) - an estimate of the maturity of a technology - is classified as TRL 8, meaning that it is a technology that has undergone large-scale testing leading to regulatory approval with further evidence generated. It is close to the most mature technology level of TRL 9, which means market access and adoption are ready.

The System is invented by a local research team led by Professor Terence Lau. Their idea of developing a fully automated, accurate, fast, and affordable multiple-pathogen molecular diagnostic device has emerged since 2015. It has been further developed to support the simultaneous detection of 40 targets, including SARS-CoV-2 which led to the COVID-19 outbreak, amid the soaring demand for timely and decentralised diagnostics in 2020.

The startup which Professor Lau co-founded has also paved the way for the System's commercialisation, and has established ISO 13485 accredited production sites in Hong Kong and the Mainland, supplying the System to hospitals and clinics for usage.

Promoting equitable access and decentralised testing

"The System can identify infectious diseases and even non-communicable diseases, and is suitable for other non-medical applications. With the support from the Research, Academic and Industry Sectors One-plus Scheme (RAISe+) from the Innovation and Technology Commission, we target to develop multiple applications to further advance the System to make it smaller, faster and more cost effective," said Professor Lau.

"With this System, we will be able to provide a comprehensive solution that can eventually promote equitable access and decentralised testing for an effective and high-quality healthcare system which WHO emphasises," he added.

"This project is a real showcase of the journey from university research to commercialisation and application, demonstrating HKBU scientists' dedication to transferring knowledge to benefit our society, not only to Hong Kong but also to the Nation and the world," said Professor Alex Wai, President and Vice-Chancellor of HKBU.

The System's clinical evaluation was carried out in two public hospitals, the Public Health Laboratory Centre, the Department of Health of the HKSAR Government, and was funded by the Public Sector Trial Scheme of the Innovation and Technology Fund. Surveillance research also started at a district center for disease control and prevention in the Mainland to develop a surveillance system that provides alerts on emerging trends of seasonal and regional prevalent pathogens, as well as early warnings on potential disease outbreaks.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

HKBU scientist's Automated Multiplex Diagnostics System recommended by WHO as an innovative health technology for low-resource contexts

HKBU scientist's Automated Multiplex Diagnostics System recommended by WHO as an innovative health technology for low-resource contexts

DURAPONTEX Grip® Innovation Offers a High-Performance Solution for Ultimate Movement Control

PORTLAND, Ore., Dec. 4, 2024 /PRNewswire/ -- Dahsheng Chemical (DSC®), a leading performance foam manufacturer, announces the launch of its latest high-performance innovation, DURAPONTEX® Grip, designed with strong grip and slip-resistant insole technology for optimal athlete control, agility, and performance.

"DURAPONTEX® Grip was inspired by an athlete's need for agile lateral movement and control on the field, court, and track," said Fennie Wei, COO of Dahsheng Chemical (DSC®). "For soccer, basketball, football, and dynamic sports that require control, the DURAPONTEX® Grip allows an athlete to confidently change direction quickly, perform lateral shuttle runs, and stop with precision for peak performance."

DURAPONTEX® Grip is constructed from advanced closed-cell foam with strong grip and slip-resistant technology, tested in both wet and dry environments. The high-resilience insole offers greater cushioning and bounce-back than traditional closed-cell foam, with resiliency scores up to 50%, using ASTM D2632. Two hardness options are available, 25 Asker C and 35 Asker C, for customized support and feel. The strong grip and enhanced cushioning support a high-intensity athlete's demands like running, sprinting, jumping, kicking, and cutting with greater control.

Earlier this year, DSC launched its Athlete Engagement Program, designed to foster deeper connections with athletes both on and off the field. Through this initiative, DSC has been actively gathering valuable feedback from athletes regarding the critical need for enhanced grip underfoot to optimize on the soccer field. Since then, DSC's developers and engineers have been testing various formulas. After numerous lab tests in both dry and wet conditions, they crafted the Durapontex® Grip, which has proven to provide stronger grip ideal for lateral movement.

DSC® will unveil DURAPONTEX® Grip at the ISPO Munich Show December 3-5, 2024 in Munich, available for attendees to experience the innovation in person.

Since its founding in 1945, Dahsheng Chemical (DSC®) has been a leader in foam innovation for the sports and bedding industries. Known for its premium comfort and performance foam DURAPONTEX® and DREAMCELL®, DSC partners with top brands and footwear manufacturers worldwide. By advancing innovation and pushing the limits of foam manufacturing, DSC® is dedicated to creating eco-friendly and advanced foam solutions that set new standards in the industry.

Visit www.dahsheng.com to learn more about Dahsheng Chemical (DSC®) and its commitment to sustainability and eco-innovation.

Media Contact:
Erin Patterson
t: +1-323-422-0274
e: erin.patterson@writetheskycomms.com

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Dahsheng Chemical Launches DURAPONTEX® Grip Insole with Slip-Resistant Technology for Enhanced Athlete Control and Agility

Dahsheng Chemical Launches DURAPONTEX® Grip Insole with Slip-Resistant Technology for Enhanced Athlete Control and Agility

Recommended Articles